These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35614113)

  • 41. Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy.
    Sabharwal V; Taglauer E; Demos R; Snyder-Cappione J; Shaik-Dasthagirisaheb YB; Parker-Kelleher S; Hunnewell J; Boateng J; Clarke K; Yuen R; Barnett ED; Wachman EM; Yarrington CD
    Am J Perinatol; 2024 May; 41(S 01):e2970-e2977. PubMed ID: 37774748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
    Du J; Zhang D; Pathakamuri JA; Kuebler D; Yang Y; Loginova Y; Chu E; Madej R; Neves JV; Singer B; Radke H; Spencer N; Rizk E; Zhang A; Lu CM; Sha MY
    Emerg Microbes Infect; 2022 Dec; 11(1):250-259. PubMed ID: 34951566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.
    Gütlin Y; Albertos Torres D; Gensch A; Schlotterbeck AK; Stöger L; Heller S; Infanti L; Barut GT; Thiel V; Leuzinger K; Hirsch HH; Buser A; Egli A
    Swiss Med Wkly; 2024 Jul; 154():3408. PubMed ID: 39137369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA).
    Wang M; Kamali-Moghaddam M; Löf L; Cortabarría Fernandez M; Díaz Codina R; Sterky FH; Åberg M; Landegren U; Zhao H
    Sci Rep; 2024 Sep; 14(1):21655. PubMed ID: 39289450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273.
    Ailsworth SM; Keshavarz B; Richards NE; Workman LJ; Murphy DD; Nelson MR; Platts-Mills TAE; Wilson JM
    Ann Allergy Asthma Immunol; 2023 Jan; 130(1):67-73. PubMed ID: 36241020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review.
    Guerra ENS; de Castro VT; Amorim Dos Santos J; Acevedo AC; Chardin H
    Front Immunol; 2022; 13():1006040. PubMed ID: 36203571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.
    Ye X; Angelo LS; Nicholson EG; Iwuchukwu OP; Cabral de Rezende W; Rajan A; Aideyan LO; McBride TJ; Bond N; Santarcangelo P; Rayford YJ; Ferlic-Stark L; Fragoso S; Momin Z; Liu H; Truong K; Lopez B; Conner ME; Rice AP; Kimata JT; Avadhanula V; Piedra PA
    Front Immunol; 2021; 12():693462. PubMed ID: 34691016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.
    Wang J; Li D; Zhou Q; Wiltse A; Zand MS
    Front Immunol; 2021; 12():696370. PubMed ID: 34386006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.
    Carta M; Marinello I; Cappelletti A; Rodolfi A; Cerrito E; Bernasconi C; Gottardo M; Dal Lago F; Rizzetto D; Barzon E; Giavarina D
    Am J Clin Pathol; 2022 Feb; 157(2):212-218. PubMed ID: 34463321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
    Perkmann T; Perkmann-Nagele N; Koller T; Mucher P; Radakovics A; Marculescu R; Wolzt M; Wagner OF; Binder CJ; Haslacher H
    Microbiol Spectr; 2021 Sep; 9(1):e0024721. PubMed ID: 34190591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of anti-SARS-CoV-2 salivary antibodies in vaccinated adults.
    Castro VT; Chardin H; Amorim Dos Santos J; Barra GB; Castilho GR; Souza PM; Magalhães PO; Acevedo AC; Guerra ENS
    Front Immunol; 2023; 14():1296603. PubMed ID: 38022522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.